Previous 10 | Next 10 |
ANI Pharmaceuticals, Inc. (ANIP) Q1 2020 Earnings Conference Call May 7, 2020 10:30 A.M. ET Company Participants Arthur Przybyl - Chief Executive Officer Stephen Carey - Chief Financial Officer Patrick Walsh - ANI Board Member Conference Call Participants Presentation ...
Image source: The Motley Fool. ANI Pharmaceuticals Inc (NASDAQ: ANIP) Q1 2020 Earnings Call May 8, 2020 , 8:30 p.m. ET Operator Continue reading
ANI Pharmaceuticals (NASDAQ: ANIP ): Q1 Non-GAAP EPS of $1.04 beats by $0.15 ; GAAP EPS of -$0.59 misses by $0.58 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BAUDETTE, Minn. , May 7, 2020 /PRNewswire/ -- For the first quarter 2020, ANI reports: Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 Adjusted non-GAAP EBITDA of $17.6 million ...
BAUDETTE, Minn. , April 30, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2020 financial results on Thursday, May 7, 2020 , before the opening of the U.S. financial markets. The earnings press releas...
BAUDETTE, Minn. , April 29, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Cortrophi...
H.P. Acthar Gel is a corticotropin injection approved to treat 19 indications, including multiple sclerosis, rheumatoid arthritis, and infantile spasms. The anti-seizure drug often requires daily dosing, and only had a list price of $40 per vial in 2000. Fast forward 20 years later, the dru...
ANI Pharmaceuticals Submit Application for Relaunching Cortrophin Gel ANI Pharmaceuticals Inc. ( ANIP ) announced that it has submitted a Prior Approval Supplement to the FDA. The supplement has been filed with the Endocrinology Division of the regulatory body. The application pertains to ...
BAUDETTE, Minn. , April 14, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that Arthur S. Przybyl will depart as President and Chief Executive Officer on May 10, 2020 . The Board of Directors has retained a nationally recognized executive sea...
The FDA has accepted for review an application from ANI Pharmaceuticals ( ANIP -2.9% ) seeking approval to re-commercialize Purified Cortrophin Gel (repository corticotropin injection USP) 80U/mL. The agency's action date is July 23. More news on: ANI Pharmaceuticals, Inc., Mallinckrod...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....